Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 2 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Results 1 - 10 of 10

Recs

0
Member Avatar g60 (23.63) Submitted: 2/25/2014 3:48:43 PM : Outperform Start Price: $3.39 CORT Score: +12.02

Armando

Recs

0
Member Avatar d3ming (51.80) Submitted: 1/31/2014 1:31:48 PM : Outperform Start Price: $3.38 CORT Score: +8.83

zzporte

Recs

0
Member Avatar cavemantrader (83.30) Submitted: 11/29/2013 1:49:45 PM : Outperform Start Price: $2.10 CORT Score: +79.58

I expect positive results for Korlym in treating psychotic depression. On top of that, without pumping, this may be one of the best buys going into 2014 at these levels, as a breakout on volume above $2.15 could set this gem up for an explosive leg up near the $5 mark. This could then lend itself to major funds buying shares, which could even take this to a whole new level. Company seems to be doing everything right, nice insider buys, and revenue continues to pick up as well. Company also states no risk of dilution on last CC.

Recs

2
Member Avatar zzlangerhans (99.73) Submitted: 11/28/2013 1:26:42 PM : Outperform Start Price: $2.10 CORT Score: +79.58

I approached my trimonthly analysis ready to gather evidence for yet another red thumb smackdown of this struggling outfit, but after reading the transcript of the last CC I decided to change things up. I'm dubious of the company's claims that Korlym will make them cash flow even without the necessity of another capital raise, and I'm skeptical about the prospects of the interminable phase III trial of Korlym for psychotic depression. Nevertheless, there was an indisputable uptick in Korlym revenue last quarter and the company has guided to continued growth of sales in Q4. The next significant catalyst is an opinion from CHMP in Q1 2014, which I expect to be positive. Last but not least, the stock has steadily appreciated since earnings and I've learned that these kinds of sustained upward moves should not be ignored in microcap biopharma.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $2.06 CORT Score: -75.76

Biotech. Just started having small revenues. Massive losses. Massive share issuance diluting shares.

Recs

0
Member Avatar bassettt (90.91) Submitted: 7/1/2011 11:44:33 PM : Underperform Start Price: $3.92 CORT Score: +41.62

This stock may be a worth less than 50 cents in a year. The drug the FDA is currently reviewing, Corlux, has the same active ingredient as the pill that is taken to eliminate early pregnancy. I don't see the FDA allowing such a drug to be distributed when Corlux would only benefit about 5-10 thousand people anyway. The rest of their pipeline is dependent on the same active ingredient.

Recs

0
Member Avatar tiobueno (99.47) Submitted: 4/4/2008 12:29:13 PM : Outperform Start Price: $3.56 CORT Score: -33.03

March 27, 2008 12:44 PM EDT

Corcept Therapeutics Inc. (Nasdaq: CORT) Director, Joseph Cook, bought 176,522 on 3/25 at $2.77, bringing his stake to 1,656,360 shares. In addition, Director, David Mahoney, bought 70,609 shares on 3/25 at $2.77, bringing his stake to 636,547 shares.

Corcept Therapeutics Incorporated develops drugs for the treatment of severe psychiatric and metabolic diseases. [LJ]

Recs

0
Member Avatar Ajiday (23.98) Submitted: 4/4/2008 7:30:22 AM : Outperform Start Price: $3.80 CORT Score: -41.33

Health, health, health! One cannot go wrong with health. And the more they specialize and branch out, the better the prospects for these companies.

Recs

0
Member Avatar elwood713 (< 20) Submitted: 4/2/2008 3:59:18 PM : Outperform Start Price: $3.79 CORT Score: -40.35

Since the inception of this stock, given it's highs and lows, the trend shows the stock outperforming the S&P 500.

Recs

0
Member Avatar godsmacks1 (< 20) Submitted: 12/19/2007 1:43:29 PM : Underperform Start Price: $2.84 CORT Score: -0.55

sub prime

Results 1 - 10 of 10

Featured Broker Partners


Advertisement